PMID: 9535248Apr 16, 1998Paper

Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory

The Pediatric Infectious Disease Journal
H AhmanJ Eskola

Abstract

Pneumococcal polysaccharide vaccines are not protective against the most common pneumococcal infections in infancy. The importance of pneumococcal diseases and emerging antimicrobial resistance emphasize the need for prophylaxis. Pneumococcal conjugate vaccine, containing capsular polysaccharides from serotypes 6B, 14, 19F and 23F conjugated to diphtheria toxoid (PncD), was given to 75 infants at 2, 4 and 6 months of age. Three dosages (1, 3 or 10 microg of each) were used. A placebo group of 49 infants received physiologic saline. Children were given a booster dose of either polysaccharide or conjugate vaccine at 14 months of age; the placebo group received conjugate vaccine. Antibody concentrations were determined with an enzyme immunoassay. The highest dose induced the strongest response after primary immunization, but booster response was greatest in the group primed with the lowest dose. Polysaccharide and conjugate vaccines induced booster responses of the same magnitude. At 24 and 36 months of age the antibody concentrations were similar in children who had received the PncD in infancy and in children immunized at 14 months of age only. The PncD conjugate vaccine is immunogenic and able to induce immunologic memory.

References

Apr 1, 1990·Clinical Microbiology Reviews·K P Klugman
Sep 2, 1994·Science·J Cohen
Sep 1, 1995·Clinical and Diagnostic Laboratory Immunology·S A QuataertD V Madore
May 1, 1996·The Journal of Pediatrics·E L AndersonP M Mendelman
Apr 1, 1996·The Pediatric Infectious Disease Journal·A LeachB M Greenwood

❮ Previous
Next ❯

Citations

Mar 24, 1999·Ryōikibetsu shōkōgun shirīzu·M KurokiS Kohno
Mar 29, 2002·Lancet·Klaus StarkUlrich Bienzle
Sep 29, 2001·Journal of Microbiological Methods·G B Lesinski, M A Westerink
Apr 23, 2003·Vaccine·Katherine L O'Brien, Ron Dagan
Oct 3, 1999·Vaccine·A A Lindberg
Jan 26, 2000·Comptes rendus de l'Académie des sciences. Série III, Sciences de la vie·A A Lindberg
Mar 18, 2000·International Journal of Antimicrobial Agents·M A Mufson
Jul 18, 2002·Scandinavian Journal of Immunology·T Wuorimaa, H Käyhty
Feb 15, 2001·The New England Journal of Medicine·J EskolaUNKNOWN Finnish Otitis Media Study Group
Jul 29, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·K M MiernykM Santosham
Dec 26, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·H Käyhty, H Ahman
Jul 3, 1999·The Pediatric Infectious Disease Journal·J Eskola, M Anttila
Apr 27, 2000·The Pediatric Infectious Disease Journal·H R Shinefield, S Black
May 23, 2000·The Pediatric Infectious Disease Journal·J Eskola, T Kilpi
Jun 22, 2002·The Pediatric Infectious Disease Journal·Taneli PuumalainenHanna Nohynek
Mar 20, 1999·Current Opinion in Pediatrics·S Choo, A Finn
Jan 6, 2005·Drugs·Jolanta Bernatoniene, Adam Finn
Mar 23, 2005·Proceedings of the National Academy of Sciences of the United States of America·Richard MalleyMarc Lipsitch
Apr 28, 2009·Expert Opinion on Biological Therapy·Alison N ThorburnPeter G Gibson
Jul 6, 2010·Vaccine·Ron DaganClaire-Anne Siegrist

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.